Huilai Zhang
Tianjin Medical University Cancer Institute and Hospital(CN)Civil Aviation University of China(CN)Sichuan Agricultural University(CN)Leukemia and Lymphoma Society(US)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, Viral-associated cancers and disorders, CNS Lymphoma Diagnosis and Treatment
Most-Cited Works
- → AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma(2019)408 cited
- → Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China(2017)247 cited
- → Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas(2016)200 cited
- → Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase(2020)179 cited
- → Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study(2019)153 cited
- → Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study(2022)152 cited